Search - tctmd.com

Displaying 1 - 20 of 32

Sort: Relevancy | Date

Presentation TCT 2016

FDA Perspectives on TAVR Label Expansion (E.G. Lower Risk Patients, Bicuspid Aortic Stenosis and Aortic Insufficiency), and New and Iterative Device Approval Pathways

Presenter: Nicole Ibrahim, Martin B. Leon, Jaime Raben

November 01, 2016

Presentation TCT 2016

Debate - Should TAVR Be Offered to Every Patient With Aortic Stenosis? No, Given All the Uncertainties About Durability, Valve Thrombus, etc. - Wait for the Data in Low-risk Patients!

Presenter: Andreas Baumbach, David Hildick-Smith, Wilson Y. Szeto

November 01, 2016

Presentation TCT 2016

Flash Debate: Counterpoint In Lower Risk Patients, A Thoughtful Hybrid Strategy Is Preferred!

Presenter: Raj Makkar, Lars Sondergaard, Stephen J.D. Brecker

October 31, 2016

Presentation TCT 2016

Flash Debate: Point In Lower Risk Patients, the Minimalist Strategy Should Be the Default Approach!

Presenter: Raj Makkar, Lars Sondergaard, Antonio Colombo

October 31, 2016

Presentation TCT 2016

TAVR for Intermediate-Risk and Low-Risk Patients: Review of the Literature

Presenter: Niall T. Mulvihill, Michael Mahmoudi

October 31, 2016

Presentation TCT 2016

Debate: Should All Low-Risk Patients With Severe Aortic Stenosis Who are Suitable Be Allowed to Choose TAVR Rather than Surgical AVR, Without Further Trial Evidence? Con Position

Presenter: Niall T. Mulvihill, Hellmuth Weich

October 31, 2016

Presentation TCT 2016

Debate: Should All Low-Risk Patients With Severe Aortic Stenosis Who are Suitable Be Allowed to Choose TAVR Rather than Surgical AVR, Without Further Trial Evidence? Pro Position

Presenter: Niall T. Mulvihill, Antoniette Neylon

October 31, 2016

Presentation TCT 2016

Introduction: TAVR in Intermediate-Risk and Low-Risk With Severe Aortic Stenosis

Presenter: Niall T. Mulvihill

October 31, 2016

Presentation TCT 2016

Debate: TAVR for Low Risk Patients Is It time? NO, We Dont Yet Know if Its as Durable as Surgical AVR!

Presenter: Russell A. Brandwein, Isaac George

October 30, 2016

Presentation TCT 2016

Debate: TAVR for Low Risk Patients Is It time? YES, the Data Is Sufficient and Our Patients Want It!

Presenter: Russell A. Brandwein, Susheel K. Kodali

October 30, 2016

Presentation TCT 2016

Real-world Requirements and Expectations for TAVR in Lower Risk Patients

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Martin B. Leon

October 30, 2016

Presentation TCT 2016

An Interesting Alternative: The New WikiRecs for TAVR Use in Lower Risk Patients

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Catherine M. Otto

October 30, 2016

Presentation TVT 2016

Study Design for the PARTNER 3 Low-Risk Trial

Presenter: Martin B. Leon

June 16, 2016

Presentation TVT 2016

Study Design for the EVOLUT R Low-Risk Trial

Presenter: Jeffrey J. Popma

June 16, 2016

Presentation TVT 2016

The Relentless Journey of TAVR to Lower-Risk Patients: Are We There Yet?

Presenter: Martin B. Leon

June 16, 2016

Presentation SOLACI 2016

Future Directions in TAVR: From Moderate-Low Risk Patients to New Devices

Presenter: Martin B. Leon

June 10, 2016

Presentation

TAVR Compared with SAVR in Low-Risk Patients

Presenter: Stefano Rosato

May 16, 2016

Presentation

Ticagrelor vs Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI

Presenter: Dominick J. Angiolillo

February 09, 2016

Presentation TCT 2015

The Case for TAVR Expansion to Lower-Risk Patients

Presenter: Martin B. Leon, Neil E. Moat, Nicolo Piazza

October 11, 2015

Presentation TVT 2015

New Indications Coming: The Role of the Heart Team in the Assessment of Intermediate- and Low-Risk Patients

Presenter: Susheel K. Kodali, David A. Wood

June 06, 2015

Advertisement

FDA Perspectives on TAVR Label Expansion (E.G. Lower Risk Patients, Bicuspid Aortic Stenosis and Aortic Insufficiency), and New and Iterative Device Approval Pathways

Debate - Should TAVR Be Offered to Every Patient With Aortic Stenosis? No, Given All the Uncertainties About Durability, Valve Thrombus, etc. - Wait for the Data in Low-risk Patients!

Flash Debate: Counterpoint In Lower Risk Patients, A Thoughtful Hybrid Strategy Is Preferred!

Flash Debate: Point In Lower Risk Patients, the Minimalist Strategy Should Be the Default Approach!

TAVR for Intermediate-Risk and Low-Risk Patients: Review of the Literature

Debate: Should All Low-Risk Patients With Severe Aortic Stenosis Who are Suitable Be Allowed to Choose TAVR Rather than Surgical AVR, Without Further Trial Evidence? Con Position

Debate: Should All Low-Risk Patients With Severe Aortic Stenosis Who are Suitable Be Allowed to Choose TAVR Rather than Surgical AVR, Without Further Trial Evidence? Pro Position

Introduction: TAVR in Intermediate-Risk and Low-Risk With Severe Aortic Stenosis

Debate: TAVR for Low Risk Patients Is It time? NO, We Dont Yet Know if Its as Durable as Surgical AVR!

Debate: TAVR for Low Risk Patients Is It time? YES, the Data Is Sufficient and Our Patients Want It!

Real-world Requirements and Expectations for TAVR in Lower Risk Patients

An Interesting Alternative: The New WikiRecs for TAVR Use in Lower Risk Patients

Study Design for the PARTNER 3 Low-Risk Trial

Study Design for the EVOLUT R Low-Risk Trial

The Relentless Journey of TAVR to Lower-Risk Patients: Are We There Yet?

Future Directions in TAVR: From Moderate-Low Risk Patients to New Devices

TAVR Compared with SAVR in Low-Risk Patients

Ticagrelor vs Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI

The Case for TAVR Expansion to Lower-Risk Patients

New Indications Coming: The Role of the Heart Team in the Assessment of Intermediate- and Low-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content